Covidien's Q4 profits hit by spin-out costs
This article was originally published in Clinica
Executive Summary
Despite recording a 5% increase in group sales for the fourth quarter of fiscal 2007, Covidien was unable to prevent higher-than-expected expenses from impacting overall profits. The company saw total earnings fall from $340m for the same period in 2006 to $34m, after it was hit by $697m worth of selling, general and administrative expenses and $290m of charges related to its spin-out from Tyco International earlier this year (see Clinica No 1244, p 12).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.